Cost, Insurance Coverage, and Access Public insurance coverage for GLP-1 obesity treatments is spotty in the United States
Ebata, T
The right choice depends on the individual patient's clinical profile
Key takeaways: GLP-1 medications are primarily used for weight loss, but are increasingly being explored in relation to PCOS and perimenopause Early evidence (mainly in women with obesity and PCOS) suggests GLP-1s may improve insulin resistance and support more regular menstrual cycles and ovulation There is currently limited research on how GLP-1 medications affect periods, fertility, PMS, or menopause symptoms in the wider population Period tracking apps like Clue may help users monitor cycle and symptom changes while using GLP-1 medications 1
And as GLP-1-based medications have become more widely used, I wanted to better understand whether these therapies, when they're prescribed for obesity or diabetes, might also affect arthritis and cardiovascular risk in our patients
Conclusion and perspective Emerging preclinical evidence suggests that GLP-1 receptor agonists (GLP-1RAs) may represent a novel class of therapeutics for pain management
